Following Abbott's Q4 report, Stifel analyst Rick Wise said the company's initial 2020 organic sales and EPS guidance, along with commentary from both current CEO Miles White and to-be-CEO Robert Ford, lead him to believe the company's top-tier growth on both the top and bottom lines seems "increasingly sustainable." White and Ford both "emphatically expressed confidence" that key drivers such as MitraClip, Libre and Alinity can deliver durable, sustainable growth in the business, said Wise. He raised his price target on Abbott shares to $104 from $95 and keeps a Buy rating on the stock.